| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione manufacturers
- C527
-
- $29.00
-
2026-07-27
- CAS:192718-06-2
- Purity: 97.64%
- Supply Ability: 10g
- C527
-
- $29.00
-
2026-07-27
- CAS:192718-06-2
- Purity: 97.64%
- Supply Ability: 10g
|
| | 2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione Basic information |
| Product Name: | 2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione | | Synonyms: | 2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione;2-(4-Fluorophenyl)-naphth[2,3-d]oxazole-4,9-dione;C527;Naphth[2,3-d]oxazole-4,9-dione, 2-(4-fluorophenyl)-;C527 >=98% (HPLC);Inhibitor,C 527,DUBs,C527,Deubiquitinase,C-527,inhibit;2-(4-Fluorophenyl)phtho[2,3-d]oxazole-4,9-dione | | CAS: | 192718-06-2 | | MF: | C17H8FNO3 | | MW: | 293.25 | | EINECS: | | | Product Categories: | | | Mol File: | 192718-06-2.mol | ![2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione Structure](CAS/20150408/GIF/192718-06-2.gif) |
| | 2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione Chemical Properties |
| Boiling point | 488.6±47.0 °C(Predicted) | | density | 1.433±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: soluble0.3mg/mL, clear (warmed) | | pka | -4.21±0.20(Predicted) | | form | powder | | color | faint yellow to dark yellow |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 46 | | WGK Germany | 3 |
| | 2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione Usage And Synthesis |
| Uses | C527 is a is a pan DUB enzyme inhibitor, with a high potency for the USP1/UAF1 complex (IC50=0.88 μM). | | Biological Activity | C527 is a pan-DUB enzyme inhibitor with high activity against USP1/UAF1 complex with IC50 value of 0.88 μM. | | in vitro | Pretreatment of USP1/UAF1 with C527 resulted in inhibition of its enzyme activity with an IC 50 of 0.88±0.03 μM. C527 inhibits the DUB activity of the USP12/USP46 complex and other DUB enzymes in vitro . However, the IC 50 of C527 for these DUB enzymes was higher in comparison with USP1/UAF1 complex. C527 has considerably less inhibitory effect on UCH-L1 and UCH-L3, a different subclass of DUB enzymes. C527 treatments causes an increase in the levels of Ub-FANCD2 and Ub-FANCI. Pretreatment of cells with the C527 causes an enhancement in the cytoxicity of mitomycin C and camptothecin. C527 treatments lead to an increase in ubiquitinated forms of FANCD2 and FANCI, cause a decrease in homologous recombination activity, and sensitize cells to DNA damaging agents. | | target | | | References | [1] Mistry H, et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013 Dec;12(12):2651-62. DOI:10.1158/1535-7163.MCT-13-0103-T |
| | 2-(4-Fluorophenyl)naphtho[2,3-d]oxazole-4,9-dione Preparation Products And Raw materials |
|